Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Argus Research Initiates Coverage On Haleon with Hold Rating

Argus Research Initiates Coverage On Haleon with Hold Rating

Argus Research analyst Taylor Conrad initiates coverage on Haleon (NYSE:HLN) with a Hold rating.

byBenzinga Newsdesk

September 28, 2022

1 minute read

Argus Research analyst Taylor Conrad initiates coverage on Haleon (NYSE:HLN) with a Hold rating.

Why Fortinet Shares Are Tumbling Today

By Lekha Gupta

August 4, 7:22 AM

Fortinet Inc (NASDAQ: FTNT) shares are trading lower by around 20% after it reported Q2 FY23 earnings results and

FTNT

News

A Look Into Financial Services Sector Value Stocks

By Benzinga Insights

April 13, 10:48 AM

What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of…

ECPG

Analyst Ratings

Analyst Expectations for XP’s Future

By Benzinga Insights

March 31, 12:01 PM

XP (NASDAQ:XP) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

Reported Late Wednesday March 22, Cidara Therapeutics And Melinta Therapeutics Announce FDA Approval Of REZZAYO For The Treatment Of Candidemia And Invasive Candidiasis

By Happy Mohamed

March 23, 12:31 AM

– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options – – REZZAYO

CDTX

Argus Research Initiates Coverage On Haleon with Hold Rating

Related Posts

Why Fortinet Shares Are Tumbling Today

A Look Into Financial Services Sector Value Stocks

Analyst Expectations for XP’s Future

Reported Late Wednesday March 22, Cidara Therapeutics And Melinta Therapeutics Announce FDA Approval Of REZZAYO For The Treatment Of Candidemia And Invasive Candidiasis